TOKYO, Feb. 2 /PRNewswire/ -- PharmaDesign Inc.(PDI) and its representative, Summit Pharmaceutical International Corp. (SPI), announced today, that SPI has signed an agreement with Merck & Co., Inc. to license PharmaGPEP, a GPCR peptide ligand library designed and produced by PDI. Financial and other terms were not disclosed.
PharmaDesign Inc. (PDI), http://www.pharmadesign.co.jp/, is a Tokyo based genomic drug discovery company, the first venture company of its kind in Japan, established in 1999. PharmaDesign offers a range of proprietary technologies in drug design research by utilizing their expertise in bio- informatics and in silico protein science.
Summit Pharmaceutical International Corp. (SPI), http://www.summitpharma.co.jp/, is an integrated drug discovery service company established in 1995 based in Tokyo. SPI has been the leader in providing whole range drug research support from discovery stage research materials and tools such as screening library for HTS, arrangement of research collaborations, through licensing arrangement of pharmaceutical products and candidates.
Summit Pharmaceuticals International Corp. (SPI)
VP & Head of Discovery Service Dept.
Summit Pharmaceuticals International Corp.
CONTACT: Katsumi Ishiguro, VP & Head of Discovery Service Dept. of SummitPharmaceuticals International Corp. (SPI), +81-3-3294-1613,email@example.com